Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Melanoma 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Ipilimumab 106 Nivolumab 101 pembrolizumab 90 aldesleukin 72 Cyclophosphamide 46 Interleukin-2 45 Temozolomide 36 Dacarbazine 32 trametinib 31 dabrafenib 30 fludarabine phosphate 29 incomplete Freund's adjuvant 27 Bevacizumab 26 sargramostim 25 Vemurafenib 25 fludarabine 22 binimetinib 21 Radiosurgery 21 Paclitaxel 20 encorafenib 19 Carboplatin 19 CTLA-4 Antigen 18 cobimetinib 16 atezolizumab 15 Radiotherapy 14 Biopsy 14 Sorafenib 13 MART-1 Antigen 12 talimogene laherparepvec 11 montanide ISA 51 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × rubitecan × Clear all

NCT00005875 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡